osimertinib
astrazeneca
['adaura', 'nsclc', 'lcsm,(-blcsm)', 'sclc', 'osimertinib', 'aura ,(-laura)']
overall survival results from the adaura trial reinforce adjuvant osimertinib as standard care for egfr-mutated, stage ib-iiia nsclc, said at #asco23. #lcsm 
https://t.co/bi63MIVP5D is a resource offering oncology health care professionals practical information about the changing clinical landscape.